Latest Healthcare News

Epsilon Healthcare has completed a $6.7 million sale and leaseback of its Southport manufacturing site, significantly reducing debt and securing long-term operational stability.

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Clever Culture Systems advances its pharmaceutical market penetration with AstraZeneca’s full deployment and Novo Nordisk’s first order, while launching a new contact plate analysis module that doubles its APAS Independence system’s capabilities.

Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Vitasora Health Limited reported a remarkable 226% increase in patient programs and secured an $11 million capital raise, positioning the company for accelerated growth and a path to cash flow breakeven in late 2026.

Osteopore Limited reports a three-fold increase in craniofacial implant sales within a year of signing an exclusive distribution deal with Zimmer Biomet, signaling strong early traction across key global markets.

Aroa Biosurgery has reported its third consecutive quarter of positive net cash flow, maintaining a strong cash position and reaffirming its FY26 revenue and EBITDA guidance. The company’s Myriad product sales continue to grow, supported by new clinical evidence.

Biome Australia Limited has delivered record sales revenue in Q4 FY25 alongside positive EBITDA, setting the stage for its first full-year net profit. Strategic product launches and international expansion underpin its strong growth trajectory.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.

Mach7 Technologies has updated its FY25 guidance, reporting positive cash flow and a solid financial position, while appointing Teri Thomas as its new CEO to steer the company’s next growth phase.